Key result
Dobutamine infusion reverses refractory hepatorenal syndrome type 1 with subclinical cirrhotic cardiomyopathy in a case report.
Why the study?
The role of positive inotropic agents in treating hepatorenal syndrome associated with cirrhotic cardiomyopathy has not been extensively evaluated.
Case Report (n=1)
No
Hepatorenal syndrome (HRS) is defined as a failure of renal function, potentially reversible, in patients with liver cirrhosis and ascites. Recently, a component of cardiomyopathy associated with HRS was described, but the use of positive inotropic medicine as part of the treatment of the acute phase has not been extensively evaluated. We report a second case in our hospital of a patient with HRS type I without previous heart disease, with secondary hemodynamic decompensation due to liver disease, in which the abnormalities in systolic function by speckle-tracking echocardiography were observed and could be reversed by the use of inotropes. After partial response to current therapies, the patient presented a clinical and laboratorial response with improvement of renal function after infusion of dobutamine. Clinical studies are needed for the therapy approach to HRS taking into account myocardial dysfunction as a major contributing factor for renal dysfunction.
No takes yet. Share an insight, caveat, or question.
Mocarzel et al. (2016) conducted a case report in Hepatorenal syndrome type I (n=1). Dobutamine vs. Standard therapy (albumin and octreotide) was evaluated on Renal function improvement. Dobutamine infusion successfully reversed renal dysfunction in a patient with refractory hepatorenal syndrome type I and subclinical cirrhotic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: